Edition:
India

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

11.41USD
21 Oct 2020
Change (% chg)

-- (--)
Prev Close
$11.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,485
52-wk High
$13.09
52-wk Low
$5.48

Becker, Marc 

Mr. Marc A. Becker serves as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer of the Company. Mr. Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics AG, a biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016, Mr. Becker served as the Chief Financial Officer of rEVO Biologics, Inc., a biotechnology company. Prior to rEVO Biologics, Mr. Becker held roles of increasing responsibility at Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A., from 2001 to 2011, culminating in Vice President, Finance. Mr. Becker received a B.S. in Business Administration from the University of Massachusetts and an M.B.A. from Babson College and was licensed as a certified public accountant.

Basic Compensation

Total Annual Compensation, USD 393,300
Restricted Stock Award, USD 288,515
Long-Term Incentive Plans, USD --
All Other, USD 1,205,600
Fiscal Year Total, USD 1,887,420

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

157,592

Roger Tung

2,772,350

Marc Becker

1,887,420

Nancy Stuart

1,908,030

James Cassella

1,695,040

Jeffrey Munsie

--
As Of  31 Dec 2019